GMED vs PODD

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

GMED

42.6
AI Score
VS
PODD Wins

PODD

45.2
AI Score

Investment Advisor Scores

GMED

43score
Recommendation
HOLD

PODD

45score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GMED PODD Winner
Revenue 2.31B 358.10M GMED
Net Income 417.04M 23.80M GMED
Net Margin 18.0% 6.6% GMED
Operating Income 510.37M 27.70M GMED
ROE 8.7% 4.7% GMED
ROA 7.5% 1.0% GMED
Total Assets 5.53B 2.29B GMED
Current Ratio 4.30 3.47 GMED
Free Cash Flow 564.16M -10.00M GMED

Relative Price Performance (Last 90 Days)

GMED 1M: -4.1% · 3M: -14.8% PODD 1M: +12.4% · 3M: +5.0%

Current Technical Phase

GMED

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.7%), weak momentum, RSI 43

RSI (14): 43.0 · Price: $73.17

PODD

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 54

RSI (14): 53.9 · Price: $150.48

Fundamentals Snapshot

Metric GMED PODD
Market Cap — —
Forward P/E 14.1 19.0
Trailing P/E 18.5 24.2
Revenue (TTM) — —
Revenue Growth 0.0% 0.2%
Gross Margin 0.7% 0.7%
Operating Margin 0.2% 0.2%
EPS 4.06 6.12
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, PODD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.